Pebody R G, Gay N J, Hesketh L M, Vyse A, Morgan-Capner P, Brown D W, Litton P, Miller E
Sero-Epidemiology Unit, Immunisation Division, PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London, UK.
Vaccine. 2002 Jan 15;20(7-8):1134-40. doi: 10.1016/s0264-410x(01)00435-2.
Measles and mumps, but not rubella, outbreaks have been reported amongst populations highly vaccinated with a single dose of measles-mumps-rubella (MMR) vaccine. Repeated experience has shown that a two-dose regime of measles vaccine is required to eliminate measles. This paper reports the effect of the first and second MMR doses on specific antibody levels in a variety of populations.2-4 years after receiving a first dose of MMR vaccine at age 12-18 months, it was found that a large proportion of pre-school children had measles (19.5%) and mumps (23.4%) IgG antibody below the putative level of protection. Only a small proportion (4.6%) had rubella antibody below the putative protective level. A total of 41% had negative or equivocal levels to one or more antigens. The proportion measles antibody negative (but not rubella or mumps) was significantly higher in children vaccinated at 12 months of age than at 13-17 months. There was no evidence for correlation of seropositivity to each antigen, other than that produced by a small excess of children (1%) negative to all three antigens. After a second dose of MMR, the proportion negative to one or more antigens dropped to <4%. Examination of national serosurveillance data, found that following an MR vaccine campaign in cohorts that previously received MMR, both measles and rubella antibody levels were initially boosted but declined to pre-vaccination levels within 3 years. Our study supports the policy of administering a second dose of MMR vaccine to all children. However, continued monitoring of long-term population protection will be required and this study suggests that in highly vaccinated populations, total measles (and rubella) IgG antibody levels may not be an accurate reflection of protection. Further studies including qualitative measures, such as avidity, in different populations are merited and may contribute to the understanding of MMR population protection.
在仅接种过一剂麻疹-腮腺炎-风疹(MMR)疫苗的高接种率人群中,已报告出现麻疹和腮腺炎疫情,但未出现风疹疫情。反复的经验表明,需要采用两剂麻疹疫苗接种方案才能消除麻疹。本文报告了第一剂和第二剂MMR疫苗对不同人群中特异性抗体水平的影响。在12至18个月龄接种第一剂MMR疫苗后的2至4年,发现很大一部分学龄前儿童的麻疹(19.5%)和腮腺炎(23.4%)IgG抗体低于假定的保护水平。只有一小部分(4.6%)的风疹抗体低于假定的保护水平。共有41%的人对一种或多种抗原呈阴性或不确定水平。12个月龄接种疫苗的儿童中,麻疹抗体阴性(但风疹或腮腺炎抗体不为阴性)的比例显著高于13至17个月龄接种疫苗的儿童。除了一小部分(1%)对所有三种抗原均呈阴性的儿童外,没有证据表明每种抗原的血清阳性之间存在相关性。接种第二剂MMR后,对一种或多种抗原呈阴性的比例降至<4%。对国家血清监测数据的检查发现,在先前接种过MMR的队列中开展MR疫苗接种活动后,麻疹和风疹抗体水平最初均有所提高,但在3年内降至接种前水平。我们的研究支持对所有儿童接种第二剂MMR疫苗的政策。然而,需要持续监测长期人群保护情况,并且本研究表明,在高接种率人群中,总麻疹(和风疹)IgG抗体水平可能无法准确反映保护情况。在不同人群中开展包括亲和力等定性指标的进一步研究是有价值的,可能有助于理解MMR疫苗对人群的保护作用。